Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
January 11, 2023
-- Product previously granted orphan drug designation for methanol poisoning -- -- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill. , Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on
November 10, 2022
Q3 2022 revenue of $3.2 million , product sales and royalty revenue up 315% from prior year and 37% from Q2 2022 Strong sales growth of ALKINDI SPRINKLE® and Carglumic Acid Third commercial product, Betaine Anhydrous, added to rare disease portfolio DEER PARK, Ill. , Nov.
November 2, 2022
DEER PARK, Ill. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, November